Search Results - "Jamotte, A."

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer by Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, J. Wang, X. Zhou, A. Gnanasakthy, K. Taylor, A. Yusuf, I. Majer, A. Jamotte, Y.-K. Kang

“…Background: In the phase II, randomized, double-blind FIGHT trial (NCT03694522), treatment with bemarituzumab plus mFOLFOX6 resulted in improvements in…”
Get full text

Measuring Treatment Effects on Rare Events Using Meta-Analysis: An Assessment of Existing Methods by Jamotte, A, Roïz, J

Get full text

Prescription patterns following First-Line Second-Generation Antipsychotics for patients with Schizophrenia in Japan: an Insurance claims database analysis by Jamotte, A, Onishi, Y, Clay, E, Aballea, S

Get full text

Review Of Methodological Approaches To Generate Propensity Scores In Multilevel Data by Sarangpur, S, Jamotte, A, Thokagevistk, K, Sherman, S

Get full text

Treatment Patterns and Health Care Costs in Patients with Schizophrenia Initiating with First- or Second-Generation Antipsychotic: Results from a Japanese Claims Database Analysis by Jamotte, A, Clay, E, Aballéa, S, Onishi, Y, Toumi, M

Get full text

Treatment Patterns and Health Care Costs in Patients with Depression Treated with Antidepressant only or Combined with Benzodiazepine: Results From a Japanese Claims Database Analysis by Jamotte, A, Clay, E, Onishi, Y, Aballéa, S, Toumi, M

Get full text

75MO Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6 by Wainberg, Z.A., Enzinger, P.C., Qin, S., Yamaguchi, K., Gnanasakthy, A., Taylor, K., Jamotte, A., Majer, I., Kang, Y-K.

Get full text

1221P Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6 by Wainberg, Z.A., Enzinger, P.C., Qin, S., Yamaguchi, K., Gnanasakthy, A., Jamotte, A., Majer, I., Kang, Y-K.

Get full text

PCN19 - Estimation of The Health Benefit Associated With A Potential Denosumab-Induced Extension of Progression Free Survival In Multiple Myeloma Patients by Sabatelli, L, Jamotte, A, Giannopoulou, C

Get full text

PRM205 - Measuring Treatment Effects on Rare Events Using Meta-Analysis: An Assessment of Existing Methods by Jamotte, A., Roïz, J.

Get full text

PMS17 - BUDGET IMPACT OF DENOSUMAB IN THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA IN COLOMBIA by Pérez, M., Jamotte, A., Amaya, J., Linares, F.

Get full text

Estimation of The Health Benefit Associated With A Potential Denosumab-Induced Extension of Progression Free Survival In Multiple Myeloma Patients by Sabatelli, L, Jamotte, A, Giannopoulou, C

“…OBJECTIVES: The efficacy of Denosumab in the prevention of skeletal-related events in multiple myeloma (MM) patients, and its non-inferiority to Zoledronic…”
Get full text

PRM72 - Review Of Methodological Approaches To Generate Propensity Scores In Multilevel Data by Sarangpur, S., Jamotte, A., Thokagevistk, K., Sherman, S.

Get full text

PMH80 - Prescription patterns following First-Line Second-Generation Antipsychotics for patients with Schizophrenia in Japan: an Insurance claims database analysis by Jamotte, A., Onishi, Y., Clay, E., Aballea, S.

Get full text

PMH74 - Treatment Patterns and Health Care Costs in Patients with Schizophrenia Initiating with First- or Second-Generation Antipsychotic: Results from a Japanese Claims Database Analysis by Jamotte, A., Clay, E., Aballéa, S., Onishi, Y., Toumi, M.

Get full text

PMH72 - Treatment Patterns and Health Care Costs in Patients with Depression Treated with Antidepressant only or Combined with Benzodiazepine: Results From a Japanese Claims Database Analysis by Jamotte, A., Clay, E., Onishi, Y., Aballéa, S., Toumi, M.

Get full text

Cost-Effectiveness of Edoxaban Compared to Warfarin for The Treatment and Secondary Prevention of Venous Thromboembolism in The UK by Clay, E, Jamotte, A, Cohen, AT, van Hout, B, Gumbs, PD, Verhamme, P

Get full text

PCV99 - Cost-Effectiveness of Edoxaban Compared to Warfarin for The Treatment and Secondary Prevention of Venous Thromboembolism in The UK by Clay, E, Jamotte, A, Cohen, AT, van Hout, B, Gumbs, PD, Verhamme, P

Get full text

PIN34 - Public Health And Economic Benefits Of Quadrivalent Influenza Vaccine In Mexico by Guerrero, ML, Jamotte, A, Tamayo, R, Hernandez, A, Galindo-Fraga, A, Ortiz, AA, Cervantes, P, Lopez, JG, Beigel, JH, Ruiz-Palacios, GM

Get full text

Public Health And Economic Benefits Of Quadrivalent Influenza Vaccine In Mexico by Guerrero, ML, Jamotte, A, Tamayo, R, Hernandez, A, Galindo-Fraga, A, Ortiz, AA, Cervantes, P, Lopez, JG, Beigel, JH, Ruiz-Palacios, GM

“…OBJECTIVES: To estimate the public health and economic burden in Mexico tnat would have been avoided, over the last 6 influenza seasons (from 2010-2011 to…”
Get full text